Prosecution Insights
Last updated: November 04, 2026
Application No. 17/864,329

HAIR GROWTH COMPOSITIONS

Final Rejection §101
Filed
Jul 13, 2022
Priority
Jul 13, 2021 — provisional 63/221,311
Examiner
CAIN, JENNIFER LYNN
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Apex Energetics Incorporated
OA Round
2 (Final)
44%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 44% of resolved cases
44%
Career Allowance Rate
28 granted / 63 resolved
-15.6% vs TC avg
Strong +68% interview lift
Without
With
+68.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
36 currently pending
Career history
116
Total Applications
across all art units

Statute-Specific Performance

§101
8.0%
-32.0% vs TC avg
§103
42.4%
+2.4% vs TC avg
§102
17.6%
-22.4% vs TC avg
§112
23.9%
-16.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 63 resolved cases

Office Action

§101
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Notice of New Examiner This case has been transferred to a new examiner for continued examination. Any further communications regarding this case may be directed to the contact information included in the conclusion of this office action. Claim Status Applicant’s remarks and amendments, filed 24 November 2025 in response to the non-final rejection mailed 22 May 2025, are acknowledged and have been fully considered. Applicant’s amendments to the claims are acknowledged. The listing of claims filed 24 November 2025 replaces all prior versions and listings of the claims. Claims 1 and 6-20 are pending. Claims 8, 9, and 20 remain withdrawn. Claims 2-5 are canceled by Applicant’s amendment. Claims 1, 10, and 14 are amended. Claims 1, 6, 7, and 10-19 are being examined on the merits. Response to Amendment Any previous rejection or objection not mentioned herein is withdrawn. Specification The disclosure is objected to because all Latinized names should be italicized with the genus name capitalized and the species name in lowercase, e.g., “Beta Pubescens Flower Bud” should instead read “Beta pubescens flower bud”. Appropriate correction is required. Claim Objections Claims 1, 6, 7, and 10-19 are objected to because all Latinized names should be italicized with the genus name capitalized and the species name in lowercase, e.g., “Beta Pubescens Flower Bud” should instead read “Beta pubescens flower bud”. All other claims depend directly or indirectly from objected to claims and are, therefore, also objected to for the reasons set forth above. Appropriate correction is required. Claim Rejections - 35 USC § 101 (maintained, grounds modified as necessitated by amendment) 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1, 6, 7, and 10-19 are rejected under 35 U.S.C. 101 because the claimed invention is directed to a judicial exception (i.e., a law of nature, a natural phenomenon, or an abstract idea) without significantly more. Claims 1, 6, 7, and 10-19 are directed to a natural product (i.e., a law of nature/a natural phenomenon). The claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception – i.e., as drafted, the claims read upon a product of nature (i.e., a law of nature/a natural phenomenon) for the following reasons: Claims 1, 6, 7, and 10-19 are drawn to a composition (for the intended use as a hair growth composition) formed entirely from natural ingredients including flower buds from Betula pubescens (e.g., downy birch tree); leaf buds from Populus nigra (e.g., black poplar tree); human hair soaked in an alcohol solvent; fungal RNA; water; alcohol; phosphorus; Castanea vesca (e.g., Castanea sativa, sweet chestnut tree); and in some cases, sugar tablets. The claimed composition is not markedly different from their naturally occurring counterparts (e.g., flower buds from downy birch trees; leaf buds from black poplar trees; human hair; fungal RNA; water; alcohol; and phosphorus, because there is no indication that the composition has any characteristics or properties that are different from the naturally occurring counterparts (including the natural compounds found therein). The cited claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception because the claims do not recite any additional elements. Furthermore, the claims do not integrate the composition into a distinguishing practical application (for example, do not broadly or specifically recite dosage form(s) and the therapeutically effective amounts of the material), but merely recites the natural materials themselves or a multiplicity of natural materials. While Claims 1, 10, 14, 18, and 19 require certain amounts of components in the active ingredient or composition, there is no indication that the amounts claimed result in a markedly different characteristic for the composition as compared to components found in nature. Therefore, the claimed composition is not deemed to be markedly different from what exists in nature in terms of structural and/or functional differences. In other words, the claims do not set forth a marked difference in terms of structural and/or functional differences (properties and/or characteristics) as compared to the naturally occurring counterparts (see, e.g., Diamond v. Chakrabarty, 447 U.S. 303(1980)). Please note that combining natural extracts (such as from two or more plants) does not remove the claims from reading upon a judicial selection (Funk Brothers Seed Col. V. Kalo Inoclulant Col. – 333 U.S. 127 (1948)) because, again, there is no evidence of a marked difference brought about by combining the instantly claimed herbal extracts. Please also note that modifying the concentration of the product/composition is not sufficient to remove the claimed composition from a judicial exception (see, e.g., Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. __, 133 S. Ct. 2107, 106 USPQ2d 1972 (2013)). Thus, when the relevant factors are analyzed, they weigh against a significant difference between the claimed invention and a judicial exception. Therefore, the claimed invention is not considered to be patent eligible subject matter. Response to Arguments Applicant's arguments filed 24 November 2025 have been fully considered but they are not persuasive. Firstly, applicant argues that the claim amendments expressly recite that Betula pubescens flower bud and Populus nigra leaf bud are present as defined hydroalcoholic extracts at a specific dilution, however the claims as presented merely require particular concentrations measured by the Centisemal scale and do not specify specific solvents. Additionally, it is noted that extraction of plants only concentrates and portions the naturally occurring compounds in the plants which are soluble or insoluble in the particular solvent. General extraction does not necessarily result in a markedly distinct change in the naturally occurring compounds from the plant. Thus, while a solvent extract itself may not be found in the nature, the compounds which are present in the plant and soluble in the selected solvent are found in nature. The creation of a solvent extract only partitions and concentrates the molecules that are naturally in the plant. There is no evidence or reason to expect that any new compounds are formed. The extract itself is a combination of the naturally occurring compounds that are simply soluble in a particular solvent. Thus, while extraction of the compounds with the selected solvent would separate a portion of the plant matter away from the naturally occurring ingredients, the result of extraction is still a combination of ingredients which are naturally found in or obtainable from the plant material; i.e., the compound is not inventive or “man-made.” Thus, each of the extracts in turn is a combination of the naturally occurring compounds found in the particular plants. Combining the extracts from the individual plants leads to a combination of the naturally occurring compounds from each of the plants and the claims are therefore drawn to combinations of naturally occurring products. Applicant goes on to argue that defined dilution levels transforms the starting materials into extracts or tinctures with markedly different characteristics with a defined dosage form. Firstly, it is noted that instant Claims 1, 10, and 14 do not require defined dosage forms. Claims 6, 7, 11, 13, and 15 are drawn to liquid compositions (e.g., a serum is a liquid), which are not markedly different from naturally occurring water or alcohol extracts. Claims 13 and 17 are drawn to administration methods, however topical, sublingual, and tablet administration forms are not markedly different from naturally occurring counterparts (e.g., a liquid can be administered topically or sublingually, and pressing into a tablet does not markedly change the properties of the composition). Additionally, absent evidence to the contrary, dilution or concentration of chemical constituents do not import structural changes relative to those found naturally within the plants, human hair, and RNA. Further, the instant disclosure does not provide evidence that undiluted extracts or that the natural counterparts themselves are incapable of providing the effects which are discussed in the disclosure, but not claimed. In response to applicant's argument that the formulations have particular effects, it is noted that the features upon which applicant relies (i.e., reduce itching and scaliness of the scalp without imparting a greasy or dirty appearance; homogenous mixture; scalp system relief; treating alopecia) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See In re Van Geuns, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993). Conclusion No claims are currently allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JENNIFER L CAIN whose telephone number is (703)756-1318. The examiner can normally be reached M-Th 5:00am to 5:00pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached at (571)272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /J.L.C./Examiner, Art Unit 1655 /AARON J KOSAR/Primary Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Jul 13, 2022
Application Filed
May 22, 2025
Non-Final Rejection mailed — §101
Nov 24, 2025
Response Filed
Oct 21, 2026
Final Rejection mailed — §101 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779366
CARNOSIC ACID, CARNOSOL AND ROSMARINIC ACID ISOLATION METHOD
4y 8m to grant Granted Nov 03, 2026
Patent 12778880
SKINCARE COMPOSITION CONTAINING SHATAVARI EXTRACT
3y 1m to grant Granted Nov 03, 2026
Patent 12766177
USE OF CRASSOCEPHALUM RABENS EXTRACT IN THE PREVENTION AND/OR TREATMENT OF FATIGUE AND/OR DEPRESSION
3y 5m to grant Granted Oct 20, 2026
Patent 12758685
ACELLULAR SOFT TISSUE-DERIVED MATRICES AND METHODS FOR PREPARING SAME
1y 7m to grant Granted Oct 13, 2026
Patent 12751924
CAROTENOID PREPARATIONS, PREPARATION METHODS, AND APPLICATION THEREOF
3y 2m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
44%
Grant Probability
99%
With Interview (+68.4%)
3y 6m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 63 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month